Tuesday 13 September 2016
Guillaume Rémy advised the funders and the company in the context of a series A financing round of €1 million by Brainvectis, a company specialized in gene therapy for neurodegenerative diseases, specifically Alzheimer’s and Huntington’s diseases, today...